Proveca

This press release is intended for investors only. Partnership aims to expand access to age-appropriate treatment for children with heart failure across 17 markets LJUBLJANA, Slovenia and MANCHESTER, United Kingdom, 20th August 2026, Lenis farmacevtika, a

This press release is intended for investors only. Proveca Receives Positive CHMP Opinion for Sialanar (Glycopyrronium) Orodispersible Tablets (ODT), Expanding Choice in the Management of Severe Sialorrhoea Positive opinion supports an innovative, orodisp

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has

This press release is intended for investors only. Proveca Signs Exclusive Licensing Agreement with LinDo K.K. for the Development and Commercialisation of Sialanar in Japan Partnership expands access to a licensed paediatric treatment for severe sialorrh

This press release is intended for investors only European Medicines Agency (EMA) adopts positive opinion for Bopediat (furosemide) as Proveca's third Paediatric Use Marketing Authorisation (PUMA) Proveca Ltd. is delighted to announce that on the 26th of

This press release is intended for investors only Proveca and BCWorld Healthcare announce the launch of the first licensed product in South Korea for the symptomatic treatment of severe sialorrhea in children and adolescents aged 3 years and older with ch

This press release is intended for investors only Proveca Ltd submits a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Aqumeldi (enalapril maleate), a prescription drug. The submission is made for the following indications:

Proveca Announces Exclusive Worldwide Development and License Agreement with Catalent for its Zydis ODT Technology for use with Glycopyrrolate Proveca, a pharmaceutical company specialising in medicines for children, announced today that it has entered in

Proveca and Cessatech announce MAA submission for CT001 to EMA on 14 August 2025. Proveca has submitted a Paediatric Use Marketing Authorisation (PUMA) application for CT001 (ketamine/sufentanil nasal spray) to the EMA The validation process has been comp

This press release is intended for investors only. Cessatech and Proveca announce world-wide excluding US commercial partnership for CT001 Cessatech and Proveca enter an exclusive agreement for the commercialization of CT001 world-wide excluding US. Prove